Inactive Instrument

Concert Pharmaceuticals, Inc.

Equities

CNCE

US2060221056

Biotechnology & Medical Research

Concert Pharmaceuticals : to Present at The JMP Securities CNS Forum

August 18, 2020 at 06:02 am EDT

Concert Pharmaceuticals, Inc. (NASDAQ: CNCE) today announced that James V. Cassella, Ph.D., Chief Development Officer, will be participating virtually in a fireside chat at The JMP Securities CNS Forum on August 19, 2020, at 10:00 a.m. ET. A live webcast of the event may be accessed in the Investors section of the Company’s website at www.concertpharma.com.

About Concert

Concert Pharmaceuticals is a clinical stage biopharmaceutical company focused on applying its DCE Platform® (deuterated chemical entity platform) to create novel medicines designed to treat serious diseases and address unmet patient needs. The Company’s approach starts with previously studied compounds, including approved drugs, in which deuterium substitution has the potential to enhance clinical safety, tolerability or efficacy. Concert’s pipeline of innovative medicines targets autoimmune diseases and central nervous systems (CNS) disorders. For more information please visit www.concertpharma.com or follow us on Twitter at @ConcertPharma or on LinkedIn.

View source version on businesswire.com: https://www.businesswire.com/news/home/20200818005174/en/

Latest news about Concert Pharmaceuticals, Inc.

Concert Pharmaceuticals Announces the Presentation of Data from its Phase 3 Clinical Trial, THRIVE-AA2	23-03-18	CI
Sun Pharmaceutical Completes Acquisition of Concert Pharmaceuticals	23-03-06	MT
Concert Pharmaceuticals, Inc.(NasdaqGM:CNCE) dropped from NASDAQ Composite Index	23-03-06	CI
Concert Pharmaceuticals, Inc.(NasdaqGM:CNCE) dropped from S&P Global BMI Index	23-03-06	CI
Concert Pharmaceuticals, Inc.(NasdaqGM:CNCE) dropped from S&P TMI Index	23-03-06	CI
Sun Pharmaceutical Industries Limited completed the acquisition of Concert Pharmaceuticals, Inc..	23-03-05	CI
Concert Pharmaceuticals, Inc.(NasdaqGM:CNCE) dropped from NASDAQ Biotechnology Index	23-03-03	CI
North American Morning Briefing : Rising Yields -3-	23-03-02	DJ
Concert Pharmaceuticals Says Deuruxolitinib Maintains FDA Breakthrough Therapy Designation to Treat Alopecia Areata	23-02-15	MT
Concert Pharmaceuticals, Inc. Maintains Deuruxolitinib Breakthrough Therapy Designation from FDA for the Treatment of Alopecia Areata	23-02-15	CI
Insider Sell: Concert Pharmaceuticals	23-01-31	MT
North American Morning Briefing : Stock Futures -3-	23-01-23	DJ
JMP Securities Downgrades Concert Pharmaceuticals to Market Perform From Market Outperform	23-01-20	MT
Truist Downgrades Concert Pharmaceuticals to Hold Rating From Buy, Adjusts Price Target to $9 From $25	23-01-20	MT
Jefferies Downgrades Concert Pharmaceuticals to Hold From Buy, Adjusts Price Target to $9 From $15	23-01-20	MT
JonesTrading Downgrades Concert Pharmaceuticals to Hold From Buy	23-01-20	MT
Indian shares set for muted start on rate hike concerns	23-01-19	RE
Sun Pharmaceutical to Acquire US-Based Concert Pharmaceuticals in $576 Million Deal	23-01-19	MT
Health Care Up Amid Deal Activity -- Health Care Roundup	23-01-19	DJ
Sector Update: Healthcare Stocks Gain on Thursday	23-01-19	MT
Sector Update: Health Care Stocks Grinding Out Modest Gains	23-01-19	MT
Sector Update: Health Care	23-01-19	MT
Concert Pharmaceuticals Shares Rally on Takeover by Sun	23-01-19	DJ
Sector Update: Health Care Stocks Flat to Lower Pre-Bell Thursday	23-01-19	MT
Sector Update: Health Care	23-01-19	MT

Chart Concert Pharmaceuticals, Inc.

Duration

Period

More charts

Company Profile

Concert Pharmaceuticals, Inc. is a late-stage clinical biopharmaceutical company. The Company is focused on developing CTP-543, a Janus Kinase 1 and Janus Kinase 2 (JAK 1/2) inhibitor that discovered through deuterated chemical entity Platform (DCE platform). The Company is evaluating CTP-543 in a Phase III clinical program for the treatment of alopecia areata, a serious autoimmune dermatological condition. Through DCE Platform, the Company has discovered and developed novel drugs designed to have properties, including enhanced clinical safety, tolerability or efficacy based on compounds. DCE technology has range of potential across numerous therapeutic areas, including for chronic diseases for which medicines are continually used by patients. The Company is assessing earlier-stage pipeline candidates as potential development candidates, including a once-daily, modified release formulation of CTP-543.

Sector

Biotechnology & Medical Research

More about the company

Sector Other Biotechnology & Medical Research

	1st Jan change	Capi.
IQVIA HOLDINGS INC.	+4.09%	43.84B
LONZA GROUP AG	+47.07%	41.25B
MODERNA, INC.	+9.45%	41.68B
CELLTRION, INC.	-10.92%	27.04B
ICON PUBLIC LIMITED COMPANY	+9.32%	25.53B
ALNYLAM PHARMACEUTICALS, INC.	-24.87%	18.18B
MEDPACE HOLDINGS, INC.	+29.70%	12.29B
CHARLES RIVER LABORATORIES INTERNATIONAL, INC.	+1.28%	12.29B
UNITED THERAPEUTICS CORPORATION	+7.78%	11.15B

Other Biotechnology & Medical Research